Top Wall Street Forecasters Revamp Owens & Minor Expectations Ahead Of Q2 Earnings

Owens & Minor (OMI) is scheduled to report Q2 earnings on August 11, with analysts anticipating a year-over-year EPS decline to $0.28 despite projected revenue growth to $2.73 billion. This follows the company's June 5 termination of the Rotech Healthcare acquisition, a development that preceded a 12.4% stock rally to $7.09 on Friday. Analyst sentiment remains mixed, with recent price target adjustments varying from Baird's raised $10 target to JP Morgan's cut $10 target and UBS's significantly reduced $13 target.

Analysis

Owens & Minor (OMI) is set to report second-quarter results with conflicting signals for investors: projected revenue is expected to rise 2.2% year-over-year to $2.73 billion, while earnings per share are anticipated to fall 22.2% to $0.28 from $0.36, indicating potential margin compression. This financial outlook follows a significant strategic event on June 5, when the company terminated its acquisition of Rotech Healthcare. Despite the forecast for lower profitability, OMI's stock recently surged 12.4% to $7.09, suggesting market optimism or a positive reaction to the cancelled deal. Analyst sentiment, however, remains highly fragmented, reflecting underlying uncertainty. Following the deal termination, Baird maintained a Neutral rating while raising its price target to $10. This contrasts with JP Morgan's Underweight rating and a price target cut to $10, and an older but still active Buy rating from UBS, which had previously lowered its target to $13. The divergence in ratings underscores a lack of consensus on the company's valuation and strategic path forward.

Key Decisions for Investors

• Investors should scrutinize the upcoming Q2 earnings release for insight into the drivers of the projected margin decline, as the recent 12.4% share price rally creates a high bar for performance.
• Critical attention should be paid to management's commentary on the earnings call regarding the rationale for the Rotech Healthcare acquisition termination and the company's revised capital allocation and growth strategy.
• Given the divergent analyst ratings from Buy to Underweight, it is prudent to exercise caution, as the lack of consensus highlights significant uncertainty that may only be resolved by the company's updated forward guidance.